• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Enteris touts Ph2 trial data for oral endometriosis therapy

January 3, 2018 By Sarah Faulkner

Enteris BioPharmaPrivately-held biotech Enteris BioPharma touted data today from a Phase IIa trial of its oral leuprolide formulation, Ovarest.

The Boonton, N.J.-based company reported that its product triggered significant suppression of estradiol, which is correlated with efficacy in treating endometriosis.

“The positive results from the Phase IIa clinical trial of Ovarest are a significant advancement towards Enteris’ goal of developing the first-ever oral leuprolide tablet for the treatment of endometriosis,” chairman & CEO Joel Tune said in prepared remarks.

“We look forward to advancing the Ovarest program into a Phase IIb trial, now that proof-of-concept has been established in our Phase IIa study.  It is our expectation that the Phase IIb trial planned for later this year will satisfy the requirements to make Ovarest a Phase III-ready asset. We also intend to begin development of additional indications for oral leuprolide including uterine fibroid tumors and prostate cancer. Multiple other potential indications, such as use in in vitro fertilization (IVF) protocols and central precocious puberty, can be envisioned which may contribute to further significant commercial success.”

The chief executive added that his company is working with financial consultant Torreya Partners to identify potential partnerships. Enteris has already inked a number of deals with players in the pharmaceutical industry, including Sanofi (NYSE:SNY). The two companies are working on developing an oral peptide for Type II diabetes.

“The oral delivery of peptides is considered a ‘Holy Grail’ within the pharmaceutical industry given the numerous benefits that such drugs could offer across the entire healthcare continuum,” Tim Opler of Torreya Partners added. “Based on our deep knowledge and experience, we believe that Enteris is at the forefront of a very large market opportunity. We look forward to working with Enteris to leverage the multiple value drivers that its Peptelligence platform and high-value internal and external development programs represent.”

Enteris’ ‘Peptellingence’ platform is designed to overcome the challenges of oral peptide delivery. A person’s gastrointestinal tract degrades and digests peptides and a normal peptide can’t break through the intestinal cell layer to be absorbed.

To tackle this problem, Enteris has developed a coating that stops the peptide from opening in the stomach. Instead, the therapy dissolves only once it reaches the small intestine.

The company also uses a compound to boost the intestinal cell layer’s permeability, temporarily widening the gaps between cells to facilitate drug transfer, Tune explained in an interview with Drug Delivery Business News.

“Six million women in the U.S. have been diagnosed with endometriosis, so [Ovarest] would help them immensely,” he said. “We’re just very excited about being able to potentially help that many patients.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Women's Health Tagged With: enterisbiopharma, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS